JP4261766B2 - Ｇタンパク質結合レセプターアゴニストおよびアンタゴニストについてのスクリーニングアッセイ - Google Patents

Ｇタンパク質結合レセプターアゴニストおよびアンタゴニストについてのスクリーニングアッセイ Download PDF

Info

Publication number
JP4261766B2
JP4261766B2 JP2000505277A JP2000505277A JP4261766B2 JP 4261766 B2 JP4261766 B2 JP 4261766B2 JP 2000505277 A JP2000505277 A JP 2000505277A JP 2000505277 A JP2000505277 A JP 2000505277A JP 4261766 B2 JP4261766 B2 JP 4261766B2
Authority
JP
Japan
Prior art keywords
cells
receptor
activity
compound
pthr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000505277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001512664A5 (https=
JP2001512664A (ja
Inventor
エフ． リチャード ブリンガースト，
尚 高須
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of JP2001512664A publication Critical patent/JP2001512664A/ja
Publication of JP2001512664A5 publication Critical patent/JP2001512664A5/ja
Application granted granted Critical
Publication of JP4261766B2 publication Critical patent/JP4261766B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2000505277A 1997-07-31 1998-07-30 Ｇタンパク質結合レセプターアゴニストおよびアンタゴニストについてのスクリーニングアッセイ Expired - Lifetime JP4261766B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/903,977 US6183974B1 (en) 1997-07-31 1997-07-31 Screening assays for G protein coupled receptor agonists and antagonists
US08/903,977 1997-07-31
PCT/US1998/015877 WO1999006535A1 (en) 1997-07-31 1998-07-30 Screening assays for g protein coupled receptor agonists and antagonists

Publications (3)

Publication Number Publication Date
JP2001512664A JP2001512664A (ja) 2001-08-28
JP2001512664A5 JP2001512664A5 (https=) 2009-02-19
JP4261766B2 true JP4261766B2 (ja) 2009-04-30

Family

ID=25418329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000505277A Expired - Lifetime JP4261766B2 (ja) 1997-07-31 1998-07-30 Ｇタンパク質結合レセプターアゴニストおよびアンタゴニストについてのスクリーニングアッセイ

Country Status (8)

Country Link
US (2) US6183974B1 (https=)
EP (1) EP1012241B1 (https=)
JP (1) JP4261766B2 (https=)
AT (1) ATE291615T1 (https=)
AU (1) AU8675098A (https=)
DE (1) DE69829483T2 (https=)
ES (1) ES2239398T3 (https=)
WO (1) WO1999006535A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4486256B2 (ja) * 1998-10-22 2010-06-23 ザ・ジェネラル・ホスピタル・コーポレイション 副甲状腺ホルモン（ＰＴＨ）および副甲状腺ホルモン関連ペプチド（ＰＴＨｒＰ）の生物活性ペプチドおよびペプチド誘導体
WO2001023521A2 (en) * 1999-09-29 2001-04-05 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
AU2002339843B2 (en) * 2001-07-23 2007-12-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
US7166463B2 (en) * 2001-11-16 2007-01-23 The Regents Of The University Of Colorado Nucleic acids encoding modified olfactory cyclic nucleotide gated ion channels
US7795220B2 (en) * 2003-03-19 2010-09-14 The General Hospital Corporation Conformationally constrained parathyroid hormones with alpha-helix stabilizers
JP4871128B2 (ja) * 2003-07-17 2012-02-08 ザ ジェネラル ホスピタル コーポレイション 高次構造的に制約された副甲状腺ホルモン（ｐｔｈ）アナログ
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US7833730B2 (en) * 2006-04-11 2010-11-16 Arena Pharmaceuticals, Inc. Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
WO2008019062A2 (en) * 2006-08-04 2008-02-14 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
CN104072606B (zh) * 2007-08-01 2017-09-22 总医院有限公司 利用g蛋白偶联受体和相关组合物的筛选方法
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
MX358161B (es) 2010-05-13 2018-08-06 The General Hospital Corp Star Analogos de hormona paratiroidea y usos para los mismos.
JP6093946B2 (ja) * 2014-02-25 2017-03-15 国立大学法人東北大学 Ｇタンパク質共役型受容体のシグナル伝達の検出方法
US11975050B2 (en) 2018-03-16 2024-05-07 The General Hospital Corporation Parathyroid hormone polypeptide conjugates and methods of their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462856A (en) 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
DE69233472T2 (de) * 1991-04-05 2006-02-09 The General Hospital Corp., Charlestown Parathormonrezeptor und dafür codierende DNA
DE4138621A1 (de) 1991-11-25 1993-06-17 Boehringer Ingelheim Int Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg

Also Published As

Publication number Publication date
AU8675098A (en) 1999-02-22
DE69829483D1 (de) 2005-04-28
US6183974B1 (en) 2001-02-06
US7033773B1 (en) 2006-04-25
ATE291615T1 (de) 2005-04-15
WO1999006535A1 (en) 1999-02-11
JP2001512664A (ja) 2001-08-28
EP1012241B1 (en) 2005-03-23
DE69829483T2 (de) 2006-04-27
EP1012241A1 (en) 2000-06-28
ES2239398T3 (es) 2005-09-16
EP1012241A4 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
JP4261766B2 (ja) Ｇタンパク質結合レセプターアゴニストおよびアンタゴニストについてのスクリーニングアッセイ
Takasu et al. Dual signaling and ligand selectivity of the human PTH/PTHrP receptor
Murray et al. Parathyroid hormone secretion and action: evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal ligands
Cheloha et al. PTH receptor-1 signalling—mechanistic insights and therapeutic prospects
Liu et al. Protein-protein interactions mediate mitochondrial cholesterol transport and steroid biosynthesis
Bliziotes et al. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake
Shimizu et al. Minimization of parathyroid hormone: novel amino-terminal parathyroid hormone fragments with enhanced potency in activating the type-1 parathyroid hormone receptor
Peschke et al. Parallel signaling pathways of melatonin in the pancreatic β‐cell
Quon et al. Tyrosine kinase-deficient mutant human insulin receptors (Met1153--> Ile) overexpressed in transfected rat adipose cells fail to mediate translocation of epitope-tagged GLUT4.
Behar et al. The human PTH2 receptor: binding and signal transduction properties of the stably expressed recombinant receptor
CN101784281B (zh) 确定g蛋白偶联受体激动剂的方法
Okada et al. A growth hormone (GH) analog can antagonize the ability of native GH to promote differentiation of 3T3-F442A preadipocytes and stimulate insulin-like and lipolytic activities in primary rat adipocytes.
Suva et al. PTH and PTHrP actions on bone
Hoare et al. Tuberoinfundibular peptide (7-39)[TIP (7-39)], a novel, selective, high-affinity antagonist for the parathyroid hormone-1 receptor with no detectable agonist activity
Phelps et al. Parathyroid hormone induces receptor activity modifying protein-3 (RAMP3) expression primarily via 3′, 5′-cyclic adenosine monophosphate signaling in osteoblasts.
WO2010006703A1 (en) G-protein coupled receptor 30 (gpr30) knockout mice as a model for cardiovascular diseases
Murrills et al. In vitro and in vivo activities of C-terminally truncated PTH peptides reveal a disconnect between cAMP signaling and functional activity
Tawfeek et al. Parathyroid hormone receptor internalization is independent of protein kinase A and phospholipase C activation
Papaioannou et al. G-protein signalling pathways and oestrogen: a role of balanced maintenance in osteoblasts
Diakov et al. Acute activation of human epithelial sodium channel (ENaC) by serum and glucocorticoid inducible kinase 1 (SGK1) requires prior cleavage of the channel’s γ-subunit at its proximal cleavage site
Sánchez-Margalet et al. Characterization of pancreastatin receptor and signaling in rat HTC hepatoma cells
JP2004511806A (ja) アッセイ
Mamidanna Comparison of PTH Peptides, PTH (1-34) and PTH (7-34): Effects on Cell Signaling, Proliferation, and Gene Expression in the Saos2 Human Osteosarcoma Cell Line
Brown et al. Physiology of parathyroid hormone and assessment of parathyroid function
HK1142808B (en) A method for determining an agonist of a g protein coupled receptor

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080828

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081002

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081009

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20081030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090126

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090206

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120220

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130220

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130220

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140220

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term